摘要
目的探究前列地尔对合并糖尿病的冠心病患者介入治疗中造影剂肾病(CIN)的预防作用。方法 126例冠心病合并糖尿病进行介入治疗的患者随机分为两组,对照组(n=63)予以常规预防治疗,观察组(n=63)在此基础上加用前列地尔预防治疗。观察对比两组CIN发生率、治疗前后肾功能情况及用药安全性。结果观察组CIN发生率为3.2%,明显低于对照组的15.9%(P<0.05)。观察组术后血清肌酐、血尿素氮、尿微球蛋白增加情况均低于对照组(P<0.05)。两组均未发生严重药物不良反应。结论对冠心病合并糖尿病介入治疗患者予以前列地尔预防性治疗,有助于进一步保护肾功能,降低CIN的发生率,且用药安全性较高。
Objective To explore the forefront in Bristol for interventional treatment of contrast nephropathy(CIN) in patients with coronary heart disease associated with diabetes mellitus.Methods 126 patients with diabetes mellitus for interventional therapy of coronary heart disease were randomly divided into two groups.Patients in control group(n = 63) received routine preventive treatment,and patients in observation group(n =63) were treated with alprostadil on the basis of treatment in control group,and the incidence of CIN,renal function before and after the treatment and safety of medication were observed and compared between these 2 groups.Results The incidence of CIN in observation group was 3.2%,and it was significantly lower than that(15.9%) of control group(P < 0.05).The postoperative levels of serum creatinine,blood urea nitrogen,increased urinary microglobulin in observation group were lower than those of control group(P < 0.05).There was no serious adverse drug reaction occurred in these 2 groups.Conclusion The preventive application of Bristol in PCI intervention in patients with coronary heart disease and diabetes mellitus is helpful for further protection of the renal function and reduce the happening of CIN,and the safety of drug is higher.
出处
《临床和实验医学杂志》
2018年第3期284-286,共3页
Journal of Clinical and Experimental Medicine
基金
中国石油天然气股份有限公司华北油田分公司科技项目(编号:2016-HB-G0401)
关键词
冠心病合并糖尿病
介入治疗
前列地尔
造影剂肾病
Coronary heart disease complicated with diabetes mellitus
Interventional therapy
Forefront
Contrast nephropathy
